ADBiotech Co., Ltd. announced that it has received KRW 4.5 billion in funding from Kiwoom Securities Co., Ltd., NH Investment & Securities Co., Ltd., Samsung Securities Co.,Ltd., Mirae Asset Securities Co., Ltd., KB Securities Co.,Ltd
April 25, 2024
Share
On April 26, 2024, ADBiotech Co., Ltd. closed the transaction.
ADBiotech Co Ltd is a Korea-based company mainly engaged in the manufacture and sale of veterinary drugs. The Company operates its business through two segments. Veterinary Medicine segment is engaged in the manufacture and sale of antibiotics, anticoccidial agents, antimicrobial agents, nervous system agents, synthetic antibacterial agents and others. The Supplementary Feed segment is engaged in the manufacture and sale of functional supplementary feeds and other products.
ADBiotech Co., Ltd. announced that it has received KRW 4.5 billion in funding from Kiwoom Securities Co., Ltd., NH Investment & Securities Co., Ltd., Samsung Securities Co.,Ltd., Mirae Asset Securities Co., Ltd., KB Securities Co.,Ltd